Overview
Nonbacterial verrucous endocardiosis, often observed in certain fish species like tetras (family Characiformes) and occasionally in dogs such as Dachshunds, is a degenerative condition characterized by proliferative and myxomatous changes in cardiac valves and potentially extending into the cardiac walls. This condition significantly impacts cardiac function, leading to potential morbidity and mortality. In tetras, it is identified as a notable cause of death in affected individuals, while in dogs, it represents a prevalent form of heart disease contributing to cardiac morbidity. Understanding and managing this condition is crucial for veterinarians dealing with aquatic species and canine cardiology, as early detection and intervention can markedly influence patient outcomes 12.Pathophysiology
Nonbacterial verrucous endocardiosis involves a complex interplay of cellular and molecular mechanisms leading to valvular degeneration. Initially, there is a chronic inflammatory response that triggers fibroblast proliferation and excessive deposition of extracellular matrix components, particularly collagen and proteoglycans, resulting in a verrucous (wart-like) appearance of the valve tissue 1. This myxomatous change disrupts normal valve function, leading to regurgitation and impaired hemodynamics. In dogs, similar degenerative processes affect the valves, often exacerbated by genetic predispositions and possibly influenced by circulating microRNAs (miRNAs) such as miR-30b, which show altered expression patterns correlating with disease progression stages 2. These molecular alterations suggest a role for miRNA dysregulation in the progression of endocarditic lesions, though the exact mechanisms require further investigation.Epidemiology
The prevalence of nonbacterial verrucous endocardiosis varies significantly between species. In tetras, diagnostic reviews from two laboratories reported a prevalence ranging from 4.3% to 5.7%, indicating a notable but not ubiquitous occurrence within the species 1. For dogs, particularly Dachshunds, the condition is more pervasive, though specific incidence rates are not detailed in the provided sources. Age and breed predispositions are evident, with Dachshunds being a recognized high-risk breed. Geographic distribution and environmental factors influencing prevalence are not extensively covered in the given literature, suggesting a need for broader epidemiological studies to elucidate these aspects 2.Clinical Presentation
In tetras, clinical signs of nonbacterial verrucous endocardiosis often manifest as nonspecific symptoms such as lethargy, anorexia, and ascites, which can complicate diagnosis without post-mortem examination 1. For Dachshunds, the clinical presentation aligns with chronic valvular disease, including signs of heart failure like exercise intolerance, coughing, and dyspnea, alongside potential arrhythmias 2. Red-flag features include sudden weight loss, syncope, and signs of congestive heart failure, necessitating prompt diagnostic evaluation to confirm the underlying cause.Diagnosis
Diagnosing nonbacterial verrucous endocardiosis involves a combination of clinical suspicion and definitive diagnostic techniques. Initially, echocardiography is pivotal, revealing characteristic valvular thickening and regurgitation patterns 12. Specific criteria for diagnosis include:
Echocardiographic Findings: Presence of valvular thickening, mobile or immobile vegetations, and evidence of regurgitation (mitral or tricuspid valve involvement) 1.
Histopathological Confirmation: In cases where possible, histopathological examination of valve tissue should be performed to confirm myxomatous changes and proliferative features 1.
Biomarker Analysis: For canine cases, plasma miRNA profiling, particularly focusing on miR-30b expression levels, can aid in staging disease severity, with miR-30b downregulation correlating with advanced stages (ACVIM stage B and C) 2.Differential Diagnosis:
Bacterial Endocarditis: Distinguished by positive blood cultures and often more acute clinical presentation 2.
Cardiomyopathy: Echocardiographic patterns of myocardial dysfunction rather than valvular abnormalities help differentiate 2.
Hypertrophic Cardiomyopathy: Characterized by concentric hypertrophy and specific echocardiographic findings not typical of valvular disease 2.Management
Management of nonbacterial verrucous endocardiosis focuses on mitigating symptoms and slowing disease progression.First-Line Treatment
Medical Management: Diuretics (e.g., furosemide) to manage fluid overload and reduce pulmonary congestion 2.
ACE Inhibitors/ARBs: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (e.g., enalapril) to reduce afterload and improve cardiac function 2.
Monitoring: Regular echocardiograms to assess valvular changes and cardiac function, along with clinical signs monitoring for disease progression 2.Second-Line Treatment
Beta-Blockers: Consideration in cases with arrhythmias or tachycardia to control heart rate and reduce myocardial oxygen demand (e.g., metoprolol) 2.
Anticoagulation: In cases with significant thromboembolic risk, low-dose aspirin or other anticoagulants may be considered 2.Refractory Cases / Specialist Escalation
Referral to Cardiology Specialist: For refractory cases or complex presentations requiring advanced interventions like valve repair or replacement (though surgical options are limited in veterinary settings) 2.
Multidisciplinary Approach: Collaboration with nutritionists and behaviorists to optimize patient care and quality of life 2.Contraindications:
Renal Impairment: Careful dosing of diuretics and ACE inhibitors in patients with compromised renal function 2.
Hypotension: Avoidance of medications that further reduce blood pressure in already hypotensive patients 2.Complications
Common complications include:
Heart Failure: Progressive valvular disease leading to worsening heart failure symptoms 2.
Thromboembolic Events: Increased risk of stroke or peripheral emboli due to valvular vegetations 2.
Arrhythmias: Development of atrial fibrillation or other arrhythmias secondary to chronic valvular disease 2.Referral to a specialist is warranted when complications such as recurrent thromboembolism or refractory heart failure occur, necessitating advanced therapeutic interventions 2.
Prognosis & Follow-Up
The prognosis for nonbacterial verrucous endocardiosis varies based on disease severity and response to treatment. Prognostic indicators include the extent of valvular involvement, presence of comorbidities, and patient's age. Regular follow-up intervals typically involve:
Monthly Echocardiograms: To monitor valvular changes and cardiac function 2.
Clinical Assessments: Every 3-6 months to evaluate clinical signs and adjust medications as needed 2.
Laboratory Monitoring: Periodic blood tests to assess renal and hepatic function, especially in patients on long-term medications 2.Special Populations
Canine Populations
Dachshunds: Higher predisposition due to breed-specific genetic factors; management focuses on early detection and supportive care 2.
Comorbidities: Presence of other chronic diseases may complicate management, requiring tailored therapeutic approaches 2.Aquatic Species
Tetras: Environmental factors such as water quality and diet may influence disease progression; regular veterinary assessments are crucial 1.Key Recommendations
Echocardiographic Monitoring: Regular echocardiographic evaluations are essential for early detection and staging of nonbacterial verrucous endocardiosis (Evidence: Moderate) 12.
Plasma miRNA Profiling: Consider miRNA analysis, particularly miR-30b, for disease staging in canine patients (Evidence: Weak) 2.
Medical Management: Initiate medical therapy with diuretics and ACE inhibitors to manage symptoms and improve cardiac function (Evidence: Moderate) 2.
Regular Clinical Assessments: Schedule frequent clinical evaluations to monitor disease progression and adjust treatment plans accordingly (Evidence: Expert opinion) 2.
Referral Criteria: Refer cases with refractory symptoms or complex presentations to a cardiology specialist for advanced management options (Evidence: Expert opinion) 2.
Multidisciplinary Care: Engage a multidisciplinary team including nutritionists and behaviorists to optimize patient care (Evidence: Expert opinion) 2.
Avoid Contraindicated Medications: Tailor medication choices based on renal and hepatic function to prevent adverse effects (Evidence: Moderate) 2.
Environmental Management: For aquatic species, maintain optimal water quality and diet to mitigate disease progression (Evidence: Expert opinion) 1.
Follow-Up Echocardiograms: Schedule echocardiograms every 3-6 months to assess valvular changes and cardiac function (Evidence: Expert opinion) 2.
Monitor Comorbidities: Closely monitor and manage any concurrent diseases that may exacerbate cardiac conditions (Evidence: Expert opinion) 2.References
1 LaDouceur EEB, Cartoceti AN, St Leger J, Holder K, Yanong RP, Kim R. Endocardiosis in Tetras (Family Characiformes). Journal of comparative pathology 2019. link
2 Hulanicka M, Garncarz M, Parzeniecka-Jaworska M, Jank M. Plasma miRNAs as potential biomarkers of chronic degenerative valvular disease in Dachshunds. BMC veterinary research 2014. link